Antiepileptic Drugs and Weight Gain
Antiepileptic drugs differ widely in their effect on weight: valproate, carbamazepine, gabapentin and pregabalin cause gain, while topiramate and zonisamide cause loss and others are neutral.
Plain English
Patient-Friendly Explanation
Drugs used to treat epilepsy and to stabilise mood are not all alike when it comes to body weight. Some of them cause clear weight gain, some cause weight loss, and several leave weight unchanged. Weight gain is reported with sodium valproate, carbamazepine, gabapentin, vigabatrin and pregabalin. Weight loss is reported with topiramate, felbamate, zonisamide, rufinamide and lacosamide. Phenytoin, oxcarbazepine, lamotrigine, tiagabine and levetiracetam are usually weight neutral. Valproate is the most studied and the weight gain it causes has been reported in anything from about one in ten to seven in ten patients across different studies, and it is one of the commonest reasons people stop taking it. The gain is not simply a matter of eating more. Valproate raises insulin and can produce insulin resistance, raises leptin while the brain becomes less responsive to it, and shifts blood fats in an unfavourable direction, with some patients also developing higher androgens and features resembling polycystic ovary syndrome. Genetic differences in how the drug is metabolised influence who is affected. Because these drugs are usually essential, the answer is rarely to stop treatment abruptly. Instead, the prescriber can weigh the options, and where the indication allows, choose or switch to an agent that is weight neutral or causes loss, while monitoring weight, waist and metabolic blood tests.
Medical
Clinical Definition
Antiepileptic drugs exert divergent effects on body weight through central and peripheral mechanisms. A systematic review of clinical trials and observational data reports weight gain with valproate, carbamazepine, gabapentin, vigabatrin and pregabalin; weight loss with topiramate, felbamate, zonisamide, rufinamide and lacosamide; and weight neutrality with phenytoin, oxcarbazepine, lamotrigine, tiagabine and levetiracetam. Valproate-associated weight gain has been reported in approximately 10% to 70% of patients in various series and is a frequent cause of non-adherence. The mechanism involves hyperinsulinaemia and insulin resistance, hyperleptinaemia with relative leptin resistance, raised circulating androgens and a polycystic-ovary-like phenotype, together with dyslipidaemia and metabolic syndrome in long-term users. A scoping review identified three mechanistic domains: hormonal dysregulation, genetic predisposition including CYP2C19 polymorphisms, CRTC1 methylation and PPAR-gamma/CD36 variants, and altered lipid metabolism. Valproate also raises uric acid and homocysteine with increased oxidative stress. Clinically, the choice of agent should be made with weight history in mind, and monitoring should include weight, waist circumference, fasting glucose, lipids and, where relevant, androgen status. Topiramate and zonisamide are sometimes used deliberately for their weight-lowering effect, though topiramate carries cognitive and renal-stone risks that limit this strategy.
Key Insight
Why It Matters
Weight gain that follows a new antiepileptic prescription is often attributed by patients to age or appetite alone, when the drug is the driver. Naming the weight profile of each agent lets the prescriber pick a neutral or weight-losing alternative where the indication permits, and it gives patients a concrete explanation. Because these drugs treat serious conditions, any change is a prescribing decision made with the neurologist or psychiatrist, never a reason to stop treatment unilaterally.
Sources
Reviewed against standard medical references.
Medically reviewed by
Family Physician & Registered Acupuncturist, Accord Medical Clinic. MBBS (NUS), Graduate Diploma in Family Medicine (NUS), Graduate Diploma in Acupuncture (Singapore College of TCM).
Last reviewed: October 2026
This page is general health education, not medical advice. Whether any treatment is appropriate for you is a decision made in consultation after assessment.
